Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy.

Du J, Yan L, Torres R, Gong X, Bian H, Marugán C, Boehnke K, Baquero C, Hui YH, Chapman SC, Yang Y, Zeng Y, Bogner SM, Foreman RT, Capen A, Donoho GP, Van Horn RD, Barnard DS, Dempsey JA, Beckmann RP, Marshall MS, Chio LC, Qian Y, Webster YW, Aggarwal A, Chu S, Bhattachar S, Stancato LF, Dowless MS, Iversen PW, Manro JR, Walgren JL, Halstead BW, Dieter MZ, Martinez R, Bhagwat SV, Kreklau EL, Lallena MJ, Ye XS, Patel BKR, Reinhard C, Plowman GD, Barda DA, Henry JR, Buchanan SG, Campbell RM.

Mol Cancer Ther. 2019 Dec;18(12):2207-2219. doi: 10.1158/1535-7163.MCT-18-0529. Epub 2019 Sep 17.

PMID:
31530649
2.

In Vitro L6 Irritation Assay Predicts Clinical Injection Site Reactions for Small Molecules.

Willy JA, Schulte NE, Kreklau EL, Walgren JL, Renninger ML, Baker TK.

Toxicol Sci. 2016 Jun;151(2):302-11. doi: 10.1093/toxsci/kfw050. Epub 2016 Mar 11.

PMID:
26969369
3.

Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.

Henry JR, Kaufman MD, Peng SB, Ahn YM, Caldwell TM, Vogeti L, Telikepalli H, Lu WP, Hood MM, Rutkoski TJ, Smith BD, Vogeti S, Miller D, Wise SC, Chun L, Zhang X, Zhang Y, Kays L, Hipskind PA, Wrobleski AD, Lobb KL, Clay JM, Cohen JD, Walgren JL, McCann D, Patel P, Clawson DK, Guo S, Manglicmot D, Groshong C, Logan C, Starling JJ, Flynn DL.

J Med Chem. 2015 May 28;58(10):4165-79. doi: 10.1021/acs.jmedchem.5b00067. Epub 2015 May 12.

PMID:
25965804
4.

Withdrawal assessment following subchronic oral ketamine administration in Cynomolgus macaques.

Walgren JL, Carfagna MA, Koger D, Sgro M, Kallman MJ.

Drug Dev Res. 2014 May;75(3):162-71. doi: 10.1002/ddr.21168. Epub 2014 Mar 5.

PMID:
24648280
5.

Biomarkers of exocrine pancreatic injury in 2 rat acute pancreatitis models.

Usborne AL, Smith AT, Engle SK, Watson DE, Sullivan JM, Walgren JL.

Toxicol Pathol. 2014 Jan;42(1):195-203. doi: 10.1177/0192623313512030. Epub 2013 Nov 27.

PMID:
24285669
6.

Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5).

Hughes RO, Rogier DJ, Jacobsen EJ, Walker JK, Macinnes A, Bond BR, Zhang LL, Yu Y, Zheng Y, Rumsey JM, Walgren JL, Curtiss SW, Fobian YM, Heasley SE, Cubbage JW, Moon JB, Brown DL, Acker BA, Maddux TM, Tollefson MB, Mischke BV, Owen DR, Freskos JN, Molyneaux JM, Benson AG, Blevis-Bal RM.

J Med Chem. 2010 Mar 25;53(6):2656-60. doi: 10.1021/jm901781q.

PMID:
20196613
7.

Peptide-based in vitro assay for the detection of reactive metabolites.

Mitchell MD, Elrick MM, Walgren JL, Mueller RA, Morris DL, Thompson DC.

Chem Res Toxicol. 2008 Apr;21(4):859-68. doi: 10.1021/tx700344m. Epub 2008 Mar 28.

PMID:
18370411
8.

Identification of novel peptide safety markers for exocrine pancreatic toxicity induced by cyanohydroxybutene.

Walgren JL, Mitchell MD, Whiteley LO, Thompson DC.

Toxicol Sci. 2007 Mar;96(1):174-83. Epub 2006 Dec 14.

PMID:
17169978
9.

Evaluation of two novel peptide safety markers for exocrine pancreatic toxicity.

Walgren JL, Mitchell MD, Whiteley LO, Thompson DC.

Toxicol Sci. 2007 Mar;96(1):184-93. Epub 2006 Dec 14.

PMID:
17169977
10.

Proteomics: recent applications and new technologies.

Elrick MM, Walgren JL, Mitchell MD, Thompson DC.

Basic Clin Pharmacol Toxicol. 2006 May;98(5):432-41. Review.

11.

Role of metabolism in drug-induced idiosyncratic hepatotoxicity.

Walgren JL, Mitchell MD, Thompson DC.

Crit Rev Toxicol. 2005 Apr-May;35(4):325-61. Review.

PMID:
15989140
12.

Lack of direct mitogenic activity of dichloroacetate and trichloroacetate in cultured rat hepatocytes.

Walgren JL, Kurtz DT, McMillan JM.

Toxicology. 2005 Aug 1;211(3):220-30. Epub 2005 Apr 21.

PMID:
15925025
13.

Application of proteomic technologies in the drug development process.

Walgren JL, Thompson DC.

Toxicol Lett. 2004 Apr 1;149(1-3):377-85. Review.

PMID:
15093284
14.

Induction of peroxisome proliferation in cultured hepatocytes by a series of halogenated acetates.

Walgren JL, Jollow DJ, McMillan JM.

Toxicology. 2004 May 3;197(3):189-97.

PMID:
15033542
15.

Effect of R(+)alpha-lipoic acid on pyruvate metabolism and fatty acid oxidation in rat hepatocytes.

Walgren JL, Amani Z, McMillan JM, Locher M, Buse MG.

Metabolism. 2004 Feb;53(2):165-73.

PMID:
14767867
16.

High glucose and insulin promote O-GlcNAc modification of proteins, including alpha-tubulin.

Walgren JL, Vincent TS, Schey KL, Buse MG.

Am J Physiol Endocrinol Metab. 2003 Feb;284(2):E424-34. Epub 2002 Oct 22.

Supplemental Content

Loading ...
Support Center